European Approval

Advanced Medical Solutions Grp PLC
15 December 2003


For Immediate Release                                  Monday, 15 December, 2003


                      Advanced Medical Solutions Group plc

              Superglue Stitching Product gets European Approval
                            LiquiBand(TM) Surgical

Winsford, UK: Advanced Medical Solutions (AIM: AMS), the global woundcare
technology company, today announces that it has received CE Mark approval for
Europe for the sale of its new Liquiband(TM) Surgical wound closure product which
uses super-glue technology to replace stitching.

The product has now been introduced into the UK market where it will be sold by
the Group's MedLogic sales team.  It has also been launched to existing European
distributors for introduction into various European countries during Q1, 2004.

LiquiBand(TM) Surgical is a novel medical device that utilises super-glue
technology for closing surgical incisions in the operating theatre and provides
benefits over conventional techniques such as suturing and stapling.

This technology has already proven to be very successful for wound closure in
the Accident and Emergency (A&E) department where MedLogic is market leader in
the UK.  MedLogic's LiquiBand(TM) product is currently used for closing over
30,000 trauma and minor surgical wounds per month.

The new Surgical product has been designed to meet the requirements of the
surgeon, nursing staff and patient.  It consists of a two-part system - a fast
setting, high strength adhesive is used to close the incision and then a liquid
adhesive film is painted over the skin.  This sets to provide a post-operative
dressing that is secure, flexible and resistant to water and bacteria.  This
form of closure also helps to minimise scarring after surgery thus providing a
good cosmetic result for the patient.

The new product has received positive feedback during clinical evaluation in the
UK where it was found to be easy to apply, provided very effective and rapid
sealing of wounds and gave excellent patient outcomes.  The global market for
wound closure is estimated at over $3 billion, of which tissue adhesives are a
rapidly growing segment.  It has been estimated that up to 40% of wounds
currently closed by sutures and staples are suitable for adhesives.  Although
these products are becoming routinely used in many A&E departments, the major
market opportunity for them is for closing surgical incisions in the operating
theatre.

Commenting on this announcement, Dr Don Evans, CEO of AMS stated:

'The approval and launch of Liquiband(TM) Surgical is a major milestone in further
exploiting our medical adhesive technology by accessing the dynamic surgical
wound closure market.  MedLogic has built a leadership position in the UK A&E
arena by focusing on end-user customer requirements and this exciting new
product is the result of extensive discussions and evaluation with all parties
involved in the closure and post-operative management of surgical incisions.'

'This launch provides AMS with a significant shift to higher value technology in
a high growth market sector.  With the product now available in the UK, we look
forward to rolling it out with existing and new distributors throughout Europe
during 2004.'


                                    - ENDS -

For further information, please contact:

Advanced Medical Solutions Group plc                  Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications                                Tel: [phone]
Tim Anderson, Mary-Jane Johnson


Notes to Editors:

Advanced Medical Solutions is a leading company in the development and
manufacture of products for the £15 billion global woundcare market.

Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.

In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives and sealants sold direct to A & E
departments or through distributors.

AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Coloplast, Smith + Nephew and Beiersdorf.



                      This information is provided by RNS
            The company news service from the London Stock Exchange